Summary

“Quality and risk people need to translate safety into business terms.”

In this Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Eric Sugalski about how MedTech professionals can communicate safety, risk, and innovation more effectively to senior leaders.

Eric brings a broad product-development perspective across engineering, manufacturing, regulatory strategy, commercialization, and early-stage MedTech leadership. He discusses why innovation and safety should not be treated as separate conversations, why risk professionals need to get involved earlier, and how safety-led thinking can reduce rework, improve alignment, and strengthen business outcomes.

The conversation also explores the siloed nature of MedTech, the need for cross-functional decision-making, and how QA/RA and risk professionals can increase their influence by connecting safety concerns to revenue, time, market success, and leadership priorities.

Listen to the full 30-minute podcast or jump to a section of interest listed below.

Chapters

00:00 – Introduction02:40 – Why MedTech innovation is moving faster05:00 – Thinking about safety beyond compliance08:00 – Safety-led innovation as a business advantage11:00 – Bringing safety into early product development13:35 – Communicating risk and safety to senior leaders16:30 – Why quality and risk need a strategic seat earlier18:45 – Translating safety into business terms20:25 – Building cross-functional leadership skills21:40 – MedTech Mindset and deeper industry conversations25:35 – Closing remarks and key takeaways

If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.

Suggested links:

LTR: Learning to Effectively Communicate Regulatory Risk.

LTR: How GenAI is Transforming Quality in MedTech.

Skool: MedTech Mindset Community by Eric Sugalski.

Key Takeaways

* Safety can be a driver of innovation, not a constraint. When safety is considered early, it can guide better requirements, reduce rework, and support stronger product decisions.

* MedTech teams are still too siloed. Engineering, regulatory, quality, clinical, and commercial teams often work with different definitions of success, which can weaken decision-making.

* Risk professionals need to get involved earlier. If quality and risk teams only enter after problems occur, their role stays corrective instead of strategic.

* Leadership influence requires business language. Translating safety and risk into time, revenue, delay, rework, and market impact helps leaders understand why action matters.

* Professional growth is proactive. Eric emphasizes that MedTech professionals must actively seek cross-disciplinary learning if they want to expand their influence.

Keywords

MedTech leadership, safety-led innovation, risk communication, medical device product development, quality leadership, regulatory strategy, cross-functional alignment, senior leadership, MedTech startups, business case for safety, patient safety, product development, commercialization, risk management, QA/RA leadership

About Erick Sugalski

Eric Sugalski is President of Tangram Medtech, where he serves as a fractional VP of Engineering for MedTech companies working to clear FDA, launch manufacturing, and build products that can succeed in the market. His work connects product development with regulatory strategy, manufacturing readiness, clinical considerations, commercial fit, and cross-functional alignment.

Eric is also founder and CEO of Ampulis, which partners with pharma companies to design and manufacture combination products, and he is involved as a MedTech investor with Robin Hood Ventures. His background spans product development, prototyping, manufacturing, human factors, regulatory affairs, supply chain, commercialization, and medical device entrepreneurship.

Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.

Disclaimer

Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.

Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe